**August 19-21, 2025** | Boston, MA

www.ipf-summit.com

**SAVE UP TO $500 BY REGISTERING BEFORE FRIDAY, JULY 18!**

WELCOME | EXPERT SPEAKERS | AGENDA | PARTNER WITH US | REGISTER YOUR PLACE

9th Annual

# IPFSummit

Accelerating Pulmonary Fibrosis Therapeutics From Discovery to Reality

## Assessing Emerging Biological Understanding, Evaluating Combination Therapy, & Delineating Endpoints Including & Beyond FVC for Transformative Efficacy

### Your 2025 Academic Thought Leaders:

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**Toby Maher**
Professor of Clinical Medicine and Director of Interstitial Lung Disease
**University of Southern California**

**Mary Strek**
Professor of Medicine
Director, Interstitial Lung Disease Program
**University of Chicago**

**Darrell Kotton**
Professor of Medicine & Director of the Center for Regenerative Medicine (CReM)
**Boston University and Boston Medical Center**

**Joyce Lee**
Professor, Medicine-Pulmonary Sciences & Critical Care
**University of Colorado Denver**

### Accompanying 30+ Leading Industry Experts:

**Susanne Stowasser**
Associate Head of Medicine, TA Inflammation
**Boehringer Ingelheim**

**Billy Fahy**
Executive Director, Early Clinical Lead, Clinical Research & Early Programs, Respiratory
**GSK**



**Carol Ann Satler**
Senior Vice President, Clinical Development
**Insilico Medicine**

**Cara Williams**
Vice President, Head of Preclinical Biology: Inflammation & Immunology
**Pfizer**

**Franck Rahaghi**
Executive Director of Cardiopulmonary, Global Medical Affairs
**United Therapeutics Corp.**

**Proud to Partner With:**

Open Source Imaging | Qureight | FibroFind | THORASYS | 东阳光 | Vitalograph | Nordic Bioscience | Worldwide Clinical Trials | strados | Rules Based Medicine | mannkind

+1 617 455 4188 | info@hansonwade.com | www.ipf-summit.com

Pulmonary Fibrosis (IPF, ILD) Drug Development

hansonwade

# Welcome to the Only Industry-Focused Summit Dedicated Solely to Advancing Pulmonary Fibrosis Therapeutics to Patients in Need

9th Annual IPFSummit

August 19-21, 2025 | Boston, MA

The two positive Phase 3 trials for Boehringer's nerandomilast, poised for the first approval in over a decade, have reignited the pulmonary fibrosis industry. What's more, PureTech Health, Endeavor BioMedicines, Insilico Medicine, Bristol Myers Squibb, and United Therapeutics are all making positive strides in their Phase 2 and 3 trials. The energy is contagious, and there's a renewed sense of optimism.

Despite the momentum, 2025 has already seen another clinical setback with Pliant Therapeutics discontinuing the BEACON-IPF 2b/3 trial for bexotegrast due to adverse events. Nonetheless, while we now have a long-overdue vote of confidence and a newly charted pathway to success, this is the moment to come together to look back, dissect both clinical setbacks and breakthroughs, and influence future decisions to bring long-awaited pulmonary fibrosis therapeutics to patients in desperate need.

The current benchmark of slowing fibrosis progression was set over 10 years ago by Nintedanib and Pirfenidone, both of which originated in oncology. With the next wave of readouts on the horizon, the questions remain: What will be the new benchmark for efficacy and safety for a therapy specifically designed to treat IPF? What can we learn from the data, the chosen endpoints, and trial designs that helped achieve success?

How are the next generation of pulmonary fibrosis drugs going to slow, halt, or even reverse, fibrosis to improve respiratory function and preserve patients' quality of life? Has TGF-β been tried and tested? Or is it simply too innately conserved as an antiviral pathway to safely target?

In 2025, we'll dive into all of this and more, including frontline physician perspectives on first-line therapy, how to demonstrate efficacy and value in an evolving landscape, and new approaches to target discovery and therapeutic development. From ADCs to RNA therapies, antifibrotics to regenerative medicine, the innovation pipeline is expanding fast, and this summit covers it all.

If ever there was a time to invest in this community and a conference, it's now. The path has been set. Join us this August to gain the full spectrum of insight needed to progress your candidate and bring better drugs to patients, faster.

I can't wait for this exceptional community to come together again. For some, I look forward to welcoming you back. For others, I can't wait to meet you for the first time!

**Olivia Grace Edwards**
Senior Program Director
**9th IPF Summit**

**150+** Global Attendees from Biopharma

**35+** World Class Expert Speakers

**10+** Hours of Face-to-Face Networking

**2** Tracks of Content for the Whole Team

**1** Brand-New Seminar Afternoon

**4** Unmissable Deep Dive Workshops

**5** World Renowned Academic KOLs

**All At: 1** Must Attend Conference

***Fernando Martinez**, Joseph D. Early Chair in Biomedical Research and Academic Chief of the Division of Pulmonary, Allergy, and Critical Care, **UMass Chan***

## A Letter from our Chairman

Dear colleagues,

Fibrotic diseases remain among the most difficult conditions we face as clinicians and investigators. Thanks to advances in our understanding of disease mechanisms, we are now entering an exciting era of therapeutic innovation and opportunity.

In idiopathic pulmonary fibrosis, we've seen major strides, from deeper biological insights to the first positive Phase 3 readouts in over a decade. These achievements have only been possible through close collaboration across academia, biotech, and clinical communities. Similar progress has been noted in non-IPF progressive fibrosing disorders with another recent Phase 3 trial. There are numerous ongoing studies across the spectrum of developmental stages.

Since chairing the very first IPF Summit, I've been privileged to witness the growth of this meeting into a vital forum for knowledge-sharing, debate, and connection. Each year, we push the conversation forward, and this year is no exception.

Under this year's theme of "Accelerating Pulmonary Fibrosis Therapeutics From Discovery to Reality," the 2025 program will spotlight progress across key areas: from new targets and mechanisms to imaging, biomarkers, trial design, and endpoints. We will also explore how regulatory and payer perspectives are shaping the future of access and adoption.

I invite you to join us for what promises to be a dynamic and forward-looking meeting, one that brings together the leading minds working to change the trajectory of fibrotic disease.

# Keeping Pace with the Industry's Momentum: What's New for 2025?

9th Annual IPFSummit
August 19-21, 2025 | Boston, MA

## Reuniting You with Your IPF Community:

abbvie · AstraZeneca · Boehringer Ingelheim · Bristol Myers Squibb · GSK · Pfizer · PLIANT · United Therapeutics Corporation · vicore pharma

## Expanding Your Network with New Participating Companies:

AnimaBiotech · calluna pharma · Centre Investigation Clinique Mauricie · Deciduous Therapeutics · gattx Therapeutics · Gatehouse Bio · Insilico Medicine · IONIS · MERCK · SENISCA · Synthis Therapeutics · trevi Therapeutics

## New Speakers:

**Susanne Stowasser**
Associate Head of Medicine, TA Inflammation
**Boehringer Ingelheim**

**Franck Rahaghi**
Executive Director of Cardiopulmonary, Global Medical Affairs
**United Therapeutics Corp**

**Cara Williams**
Vice President, Head of Preclinical Biology: Inflammation & Immunology
**Pfizer**

**Carol Ann Satler**
Senior Vice President, Clinical Development
**Insilico Medicine**

**Eric White**
Senior Clinical Program Lead, ILD
**Boehringer Ingelheim**

## New Cutting-Edge Content:

### Refreshed Deep Dive Workshops

Our 2025 workshops have been fully refreshed to spark bold conversations and deeper learning through highly interactive, thought-provoking discussions. From **Decoding Disruptions in Biological Processes: Unravelling Immune Cell Biology & Inflammation**, to **Innovations in Statistical Design: Optimizing Sample Size, Integrity & Trial Success**, these workshops are designed to deepen your expertise and accelerate clinical translation. Don't miss your opportunity to learn, challenge, and grow.

### Unrivalled Forward Thinking Strategy Sessions

With the field energized by positive Phase 3 results and the first potential IPF approval in over a decade, paired with looming patent expirations, it's a pivotal moment to rethink strategy. Go beyond the data with **cutting-edge sessions exploring real-world efficacy on background SOC, placebo design, patient recruitment, and more.** Equip yourself with the next wave of strategic considerations to drive smarter development in an evolving landscape.

### Brand-New Setbacks to Solutions Seminar Afternoon

We've introduced a brand-new, dedicated seminar afternoon: **"Looking Back at Phase 2/3 Clinical Trial Failures to Pave the Path Forward."** This original and thought-provoking session dissects where recent IPF programs fell short, offering critical, actionable insights to refine future clinical strategies, de-risk development, and increase the likelihood of success.

### Clinicians Thoughts on First Line Therapy

Gain firsthand insights from leading clinicians and academic experts treating IPF patients daily. Explore how they envision the integration of emerging therapies into first-line treatment paradigms, balancing efficacy, tolerability, and patient-specific considerations. **Discover how your candidate could fit within their evolving clinical decision-making frameworks.**

# The IPF Therapeutic Journey

9th Annual IPFSummit
August 19-21, 2025 | Boston, MA

## A Timeline of Milestones, Misses & Momentum

**Why This Timeline Matters:** The last decade in IPF drug development has been defined as much by hard-won lessons and high-profile failures as it has by progress. With a string of disappointing clinical outcomes and therapeutic stagnation, the field has often struggled to maintain momentum and hope. This timeline has been curated to reflect both the challenges and breakthroughs that have shaped the current landscape, charting key trial results, regulatory decisions, and emerging approaches that now point to a long-awaited turning point.

With Boehringer Ingelheim's nerandomilast poised to become the first new approved therapy in over a decade, 2025 represents a critical inflection point for the community.

The 9th IPF Summit stands apart as the only meeting bringing together every corner of the ecosystem to unpack this evolving narrative, from translational innovation and target rethinking to payer positioning and real-world impact. If you want to understand how we got here, and more importantly, where we're heading next, this is the room to be in.

**2014**

Nintedanib was approved by the FDA for the treatment of idiopathic pulmonary fibrosis on *October 15, 2014*.

*October 2014*, Pirfenidone was approved by the FDA

**2021**

*February, 2021* Galapagos and Gilead announced announce discontinuation of the ISABELA Phase 3 Study for ziritaxestat due benefit-risk profile no longer supported

**2022**

*January, 2022*, Genentech/Roche's primary patent for Esbriet®(pirfenidone) expires

*May, 2022* Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis

**2023**

*June, 2023* FibroGen announce pamrevlumab failed to meet primary endpoint in Phase 3 Study in IPF and discontinuation of study

*August, 2023* Galecto announce GALACTIC-1 Phase 2b trial of inhaled GB0139 did not meet its primary endpoint and discontinuation of study

*August 2023* Lupin Limited gains FDA approval for to market a generic equivalent of Esbriet® Tablets

**2024**

*September, 2024* Boehringer Ingelheim announces FIBRONEER™-IPF Phase 3 Study for nerandomilast meets its primary endpoint in the largest trial in idiopathic pulmonary fibrosis conducted to date

**MAJOR BREAKTHROUGH**

**2025**

*February, 2025,* Boehringer Ingelheim announces FIBRONEER™-ILD Phase 3 Study for nerandomilast meets its primary endpoint in progressive pulmonary *fibrosis*

*March, 2025* Pliant Therapeutics announces discontinuation of BEACON-IPF 2b/3 trial for bexotegrast in IPF due to adverse events in the treatment arms compared to placebo.

**THE FUTURE**

**2026**

*April, 2026* Boehringer Ingelheim's Ofev (nintendanib) primary composition of matter patent expires in US

*2025/2026* Approval of Boehringer Ingelheim's nerandomilast for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

**2029**

*Late 2029* – Expected entries of generic versions of nintedanib to enter the U.S. market





+1 617 455 4188 info@hansonwade.com www.ipf-summit.com
Pulmonary Fibrosis (IPF, ILD) Drug Development
hansonwade

# Your 38+ Expert Speakers

9th Annual IPFSummit
August 19-21, 2025 | Boston, MA

## Leading Academics & Clinicians

**Toby Maher**
Professor of Clinical Medicine and Director of Interstitial Lung Disease
**University of Southern California**

**Justin Oldham**
Associate Professor & Director, Interstitial Lung Disease Research
**University of Michigan**

**Darrell Kotton**
Professor of Medicine & Director of the Center for Regenerative Medicine (CReM)
**Boston University and Boston Medical Center**

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**Mary Strek**
Professor of Medicine
Director, Interstitial Lung Disease Program
**University of Chicago**

**Joyce Lee**
Professor - Medicine-Pulmonary Sciences & Critical Care
**University of Colorado Denver**

**Emilie Millaire**
Respirologist
**CIC Mauricie inc**

## Founders & C-Level Executives

**Lorna Harries**
Chief Scientific Officer & Founder
**Senisca Ltd**

**Dori Thomas-Karyat**
Chief Executive Officer
**Synthis Therapeutics, Inc**

**Eugenia Ruiz**
Chief Scientific Officer
**GAT Therapeutics**

**Iris Alroy**
Co-Founder & Scientific Chief & Officer
**Anima Biotech**

**Robin Mansukhani**
Chief Executive Officer
**Deciduous Therapeutics**

**Brian Windsor**
President & Chief Executive Officer
**Rein Therapeutics**

**Marco Quarta**
Co-Founder and Chief Scientific Officer
**Rubedo Life Sciences**

**James Cassella**
Chief Development Officer
**Trevi Therapeutics**

**David Salzman**
Founder & Chief Executive Officer
**GATEHOUSE BIO**

**Jonas Hallén**
Chief Medical Officer & Co-Founder
**Calluna Pharma**

**Ahmed Mousa**
Chief Executive Officer
**Vicore Pharma Holding**

**Bertil Lindmark**
Chief Medical Officer
**Vicore Pharma Holding**

**Cory Hogaboam**
Chief Scientific Officer
**Rein Therapeutics**

**Lee Borthwick**
Chief Scientific Officer, FibroFind & Senior Lecturer, Fibrosis Biology
**Newcastle University**

# Industy Leading Expert Speakers

**Eric White**
Senior Clinical Program Lead, ILD
**Boehringer Ingelheim**



**Carol Ann Satler MD PhD**
Senior Vice President, Clinical Development
**Insilico Medicine**

**Susanne Stowasser**
Associate Head of Medicine, TA Inflammation,
**Boehringer Ingelheim**

**Raghu Kumar Penke**
Senior Scientist, Drug Discovery
**Ionis Pharmaceuticals**

**Cara Williams**
Vice President, Head of Preclinical Biology
**Inflammation & Immunology**

**Jalpa Patel**
Scientific Director-Specialty Pipeline & Global Medical Affairs
**Abbvie**

**Paul Ford**
**Independent Consultant**
Former Chief Medical Officer of **Galecto**

**Travis Barr**
Principal Scientist, Biology Discovery, Fibrosis Team,
**Merck & Co**

**Aditya Patel**
Executive Director, Pulmonary Clinical Development
**Bristol Myers Squibb**

**Franck Rahaghi**
Executive Director of Cardiopulmonary, Global Medical Affairs
**United Therapeutics Corp.**

**Min Lu**
Executive Director, Biology
**Eli Lilly & Co.**

**Matthew Thomas**
Department Head of Immunology & Respiratory Diseases Research
**Boehringer Ingelheim**

**Billy Fahy**
Executive Director - Early Clinical Research Programs & Respiratory Lead
**GSK**

**Peter Schafer**
Chair, Prognostic Lung Fibrosis Consortium (PROLIFIC)
**Pulmonary Fibrosis Foundation**

**Chris Barnes**
Vice President - Biometrics
**Pliant Therapeutics Inc.**

**Elizabeth Estes**
Executive Director
**OSIC ILD**

**Camilla Graham**
Senior Vice President, Medical Affairs
**PureTech Health**

# Pre-Conference Workshop Day
## Tuesday, August 19





7:00 – 8:00 Check in & Light Breakfast

## Track 1: Emerging Biology & Early Translational

### Workshop A

**8:00 Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation**

Understanding the complex interplay between immune responses, epithelial dysfunction, and regeneration failures is crucial for advancing early intervention strategies in IPF. This workshop will explore the molecular underpinnings of immune cell activity, inflammation, and epithelial repair in disease progression. Through expert insights, we will dissect how disrupted biological processes drive fibrosis and discuss emerging therapeutic approaches targeting immune and epithelial pathways.

**Get ready to explore:**

**Epithelial Dysfunction & Regeneration Failure in IPF**
- The molecular biology of epithelial injury and its role in disease progression
- Why failed regeneration is central to fibrosis development
- Emerging biomarkers linking epithelial signatures to disease severity

**The Enigmatic Role of Inflammation in IPF**
- Understanding the paradox: why anti-inflammatory therapies worsen outcomes
- The potential of immune-targeting therapies and companies exploring this space

**Bridging Immunology & Fibrosis in IPF Treatment**
- Key immune players: which inflammatory cells are present, and what role do they play?
- How immune modulation could be leveraged for therapeutic intervention
- The next steps in developing immune-based therapies for IPF

**Travis Barr**, Principal Scientist, Biology Discovery, Fibrosis Team, **Merck & Co**

**Min Lu**, Executive Director, Biology, **Eli Lilly & Co.**

**Cory Hogaboam**, Chief Scientific Officer, **Rein Therapeutics**

## Track 2: Late Translational & Clinical

### Workshop C

**8:00 Innovating Endpoints in IPF: Including & Beyond FVC to Determine Clinical Efficacy**

FVC remains the standard endpoint for IPF clinical trials, yet its variability poses challenges for trial reliability, cost, and regulatory approval. As the field advances, there is a growing need to refine clinical trial endpoints by integrating additional, more predictive measures. This workshop will explore innovative approaches to endpoint selection, incorporating lessons from other respiratory diseases and data-driven strategies to enhance trial sensitivity and efficiency.

**Get ready to explore:**

**Addressing the Limitations of FVC**
- Understanding the variability of FVC, its impact on trial design, and the need for complementary or alternative measures to improve accuracy and trial success

**Learning from Composite Endpoints in Pulmonary Arterial Hypertension**
- Evaluating how composite endpoints, including six-minute walk distance, respiratory hospitalizations, and imaging biomarkers, can provide a more robust efficacy assessment

**Advancing Clinical Trial Design**
- Leveraging quantitative, data-driven approaches to define novel composite endpoints that enhance sensitivity, support regulatory approval, and transform the future of IPF clinical trials

**Jalpa Patel**, Scientific Director, Specialty Pipeline & Global Medical Affairs, **Abbvie**

10:30 Morning Break

# Pre-Conference Workshop Day
## Tuesday, August 19





## Workshop B

### 11:00 Genetic & Familial IPF: Uncovering Susceptibility & Resilience to Improve Early Detection & Identify Novel Therapeutic Targets

While genetic predisposition plays a role in IPF, not all individuals with risk factors develop the disease. Understanding both susceptibility and resilience can provide critical insights into early detection and potential therapeutic strategies. This workshop will explore the latest advancements in genetics, familial risk factors, and emerging research on protective mechanisms that could inform new treatment approaches.

**Get ready to explore:**

**Understanding Resiliency: Why Do Some Individuals Avoid IPF Despite Risk Factors?**
- Exploring why some high-risk individuals never develop lung disease
- Identifying protective biological mechanisms that could inform new therapies
- Reviewing emerging research on cellular and molecular markers of resilience

**Genetics & Familial Risk Factors: Improving Early Detection**
- Investigating hereditary risk factors and genetic polymorphisms in IPF
- Leveraging familial studies and at-risk cohort screenings for early diagnosis
- Exploring predictive modeling and polygenic risk scores

**Beyond Known Genetics: Novel Research & Therapeutic Targets**
- Examining new genetic discoveries beyond well-known mutations
- Understanding gene-environment interactions and epigenetics in IPF
- Exploring industry efforts in gene-targeted therapies and prevention

**Joyce Lee**, Professor, Medicine-Pulmonary Sciences & Critical Care, **University of Colorado Denver**

## Workshop D

### 11:00 Statistical Innovations & Considerations – Optimizing Sample Size, Trial Design & Data Integrity to Streamline Clinical Development

Effective clinical trial design in IPF is constrained by patient scarcity, high costs, and the need for robust statistical methodology to drive confident decision-making. This workshop will bring together statistical experts, clinical researchers, and industry professionals to explore how innovative statistical approaches can optimize sample sizes, improve trial efficiency, and mitigate the risks of underpowered studies.

**Key discussion points:**

**Balancing Statistical Rigor with Feasibility in Trial Design**
- How can we determine the optimal sample size that maintains statistical power while reducing costs and recruitment timelines?
- What alternative statistical methodologies can be applied to small patient populations to maximize data reliability?

**Mitigating the Risks of Small, Underpowered Studies**
- Explore historical IPF trial failures due to inadequate proof-of-concept data and lessons learned
- How to design early-phase trials to better de-risk phase three studies while working within financial constraints

**Addressing Data Integrity & Outlier Impact**
- The role of extreme outliers in phase two datasets—when should they be excluded or accounted for?
- Statistical innovations for improving disease modelling, endpoint selection, and predictive power of early-phase studies

This workshop will provide practical insights into statistical frameworks that enhance the success of clinical trials in IPF, ensuring more efficient study designs that improve the likelihood of regulatory success and commercial viability

**Chris Barnes**, Vice President, Biometrics, **Pliant Therapeutics Inc.**

**1:30 Lunch Break**

# Pre-Conference Workshop Day
## Tuesday, August 19





## Setbacks to Solutions Seminar Afternoon

### Looking Back at Phase 2/3 Clinical Trial Failures to Pave the Path Forward

The path to an approved IPF therapy is filled with challenges, and recent phase 2 and 3 trial failures have highlighted critical gaps in target validation, trial design, patient selection, and endpoint measurement. By analyzing where these programs faltered, we can extract actionable insights to refine future clinical strategies, de-risk development, and improve the probability of success. This seminar will bring together experts to dissect these lessons and explore how we can reshape the IPF therapeutic landscape moving forward.

**Cara Williams**
Vice President, Head of Preclinical Biology: Inflammation & Immunology
**Pfizer**

**2:30** **Breaking Down the Science: Did the Biology Fall Short?**

Scientific missteps in target selection, mechanism validation, and translational predictability often set trials up for failure before they begin. This session will examine the biological assumptions that contributed to past setbacks and how we can improve early-stage decision-making.

- Target Selection & Validation: Were we confident in the mechanism of action before advancing to the clinic? Did preclinical models confirm target engagement and therapeutic relevance?
- Translational Gaps & Dosing Challenges: Did preclinical studies establish that effective doses were achievable in humans? Were PK/PD models predictive of clinical exposure and response?
- Fibrotic Pathways & Patient Variability: How did inter-patient heterogeneity impact response? Did we overlook key immune or regenerative mechanisms that may have influenced outcomes?

**Paul Ford**
**Independent Consultant**
Former Chief Medical Officer of **Galecto** & Former Vice President & Therapeutic Area Head Respiratory Medicine
**Galapagos**

**3:00** **Preclinical & Translational Decisions: Did We Build a Strong Enough Case for Success?**

Many failed trials reveal weaknesses in preclinical rigor and translational assumptions, including inadequate target engagement studies, incomplete biomarker strategies, or insufficiently powered phase 2 trials.
Preclinical Strategy & Target Confidence: Did we truly establish a direct link between the target and IPF pathogenesis? Were preclinical efficacy signals robust, or were they driven by artificial conditions?

- Dosing, PK/PD & Translation to Humans: Was there a clear therapeutic window? Were effective concentrations realistically achievable in patients, or did preclinical studies rely on unrealistic drug levels?
- Early-Stage Trial Design & Biomarkers: How can we optimize early clinical studies to ensure meaningful phase 2 readouts? Are small, underpowered trials leading to misleading efficacy signals that don't hold up in phase 3?

**Toby Maher**
Professor of Clinical Medicine and Director of Interstitial Lung Disease
**University of Southern California**

**3:30** **Clinical Trial Design: Were We Set Up for Success?**

A well-designed clinical trial can make or break a promising therapy. This session will explore how trial design choices, endpoints, patient selection, and statistical power, have influenced past outcomes.

- Endpoints & Study Duration: Were phase 2 trials too short or underpowered to detect meaningful effects? Did reliance on FVC as the primary endpoint contribute to misleading signals?
- Patient Selection & Inclusion Criteria: Did we include the right patient populations, or was disease heterogeneity overlooked? Were exclusion criteria too broad or too restrictive?
- Statistical Pitfalls & Misleading Readouts: How often have positive phase 2 results been driven by outliers? Could alternative trial designs, such as adaptive approaches, improve decision-making?

**4:00** **Afternoon Break**

**4:30** **Audience Discussion: Learning from Failure – What Should We Do Differently?**

This interactive discussion invites all attendees to reflect on the key insights from the seminar and explore practical ways to refine IPF drug development strategies.

- Which preclinical and translational gaps have been most problematic, and how do we address them?
- What changes are needed in early clinical development to improve the likelihood of success in phase 3?
- How can industry and academia collaborate more effectively to de-risk future programs?

This session will provide a platform for open discussion, allowing attendees to share perspectives and generate actionable next steps for improving IPF clinical development.

**5:30** **Chairs Summary & Conclusions**

"High quality speakers, exhibitors, and well-organized meeting agenda, an excellent learning experience for newcomers"

**Viva Star Biosciences**

"Fantastic meeting overall! Very helpful for someone like me who is just entering the IPF field, especially the workshops. I appreciate the separation between preclinical and clinical tracks. Enjoyed the open discussions during the workshops and expert panels"

**University of Massachusetts Medical School**

# Conference Day One
## Wednesday, August 20





**7:00** **Check in & Light Breakfast**

**Olivia Grace Edwards**
**Hanson Wade**

**8:05** **Program Director's Welcome**

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**8:15** **Chairs Opening Remarks**

## Understanding & Adapting to a Changing Pulmonary Landscape with an Evolving Treatment Paradigm

**Susanne Stowasser**
Head of Clinical Development and Medical Affairs, Pulmonology
**Boehringer Ingelheim**

**8:30** **Nerandomilast as a New Benchmark in Pulmonary Fibrosis: Lessons Learned from the Clinical Development Program**

- How did the preclinical and translational data inform the design of the phase II and phase III trials? What were the key trial design features, patient populations, endpoints, and readouts that contributed to the successful outcome?
- How were the insights from both preclinical and clinical stages integrated into a cohesive development strategy that led to a positive phase III readout? What can we learn for future trials in IPF?

**9:00** **Patient Voice**

**9:15** **Panel Discussion: Navigating the Evolving IPF Treatment Landscape: Implications for Drug Discovery & Development**

With Nintedanib and Pirfenidone approaching patent expiration, the IPF treatment landscape is at a pivotal moment. The industry is now exploring next-generation therapies, combination strategies, and novel mechanisms of action to address the remaining unmet needs in fibrosis progression and lung function preservation. However, as new therapeutic approaches emerge, challenges arise in clinical trial design, endpoint selection, and regulatory pathways.

This panel will examine the evolving IPF treatment paradigm, discuss the role of combination therapy, and explore how the upcoming shifts will influence drug discovery, clinical development, and patient outcomes.
Discussion Points:

- What impact will the upcoming patent expirations of Nintedanib and Pirfenidone have on innovation and investment in IPF drug development?
- How are combination therapy strategies shaping the future of IPF treatment, and what are the key scientific and regulatory hurdles to address?
- What lessons can we learn from the development of past fibrosis treatments to optimize clinical trial design, including endpoints beyond FVC?
- With new mechanisms in development, what biomarkers and surrogate markers can better predict treatment efficacy and guide future therapeutic strategies?
- How do we ensure that novel therapies advance patient outcomes while maintaining accessibility and regulatory compliance in an evolving landscape?
- How evolving payer expectations around value, outcomes, and cost-effectiveness should inform early clinical trial design in IPF to support future market access, especially as next-generation therapies and combination strategies emerge.

**Eric White**
Senior Clinical Program Lead, ILD
**Boehringer Ingelheim**

**Carol Ann Satler**
Senior Vice President, Clinical Development
**Insilico Medicine**

**Bertil Lindmark**
Chief Medical Officer
**Vicore Pharma**

**Camilla Graham**
Senior Vice President, Medical Affairs
**PureTech Health**

# Conference Day One
## Wednesday, August 20



**10:00 Speed Networking**

This informal session provides the perfect opportunity to connect with the industry frontrunners and key opinion leaders in the pulmonary fibrosis field. Establish meaningful connections to build upon for the rest of the conference and gain exclusive first-hand insights into the latest research and developments driving progression in the pulmonary fibrosis field.

**10:45 Morning Break**

## Track 1: Emerging Biology & Early Translational

### Maximising Preclinical Packages to Provide Enhanced Confidence in Candidate Selection

**11:00 Building the Foundation for Success: Unpacking the Discovery & Preclinical Development of Nerandomilast**

- What were the key scientific hypotheses and mechanistic insights that shaped the discovery of Nerandomilast, and how was its target pathway prioritized for development?
- Which preclinical models, assays, and biomarkers were instrumental in demonstrating early efficacy and translatability? What differentiated these findings from past failures in the field?
- How did the integration of pharmacodynamic data, toxicology, and translational biomarkers enable informed decision-making and de-risk progression into clinical trials?

**Matthew Thomas**, Department Head, Immunology & Respiratory, **Boehringer Ingelheim**

**11:30 Enhancing Translational Confidence: Human-Led Drug Discovery & Model System Validation**

- Leveraging human-derived data and cross-institutional data sharing to uncover novel therapeutic targets in IPF with higher confidence
- Using multi-omics approaches to deeply characterize pulmonary fibrosis preclinical model systems and align them with human biology
- Building robust translational bridges between patient data and discovery platforms to refine candidate selection and de-risk early development

**Billy Fahy**, Executive Director, Early Clinical Lead, Clinical Research & Early Programs, Respiratory, **GSK**

## Track 2: Late Translational & Clinical

### Demonstrating Efficacy & Value in a Maturing Landscape with Background Standards of Care

**11:00 Exploring Multi Marker Modelling to Inform Prediction Modelling for Optimizing Patient Selection**

- Exploring multi-marker modeling and the potential of combining biomarkers to improve prognostication and patient selection for ILD clinical trials
- Assessing how biomarkers can be used to predict treatment response in ILD
- Evaluating multi-modal biomarker strategies that incorporate data from clinical, genomic, proteomic, and imaging domains to improve outcome discrimination in ILD

**Justin Oldham**, Associate Professor & Director, Interstitial Lung Disease Research, **University of Michigan**

**11:30 Designing Feasible, Efficient & Effective Clinical Trials in an Era of Expanding Treatment Options**

- Explore challenges in patient recruitment, including identifying patients still at risk of disease progression despite SOC treatment
- Optimize inclusion/exclusion criteria and trial design to ensure feasibility while maintaining clinical relevance in a rapidly evolving treatment landscape
- Examine how study design and statistical analyses must adjust for background therapy's impact on FVC decline, hospitalization rates, and mortality

**Brian Windsor**, President and Chief Executive Officer, **Rein Therapeutics**

# Conference Day One
# Wednesday, August 20





**12:00 Roundtable Discussion: Advancing Modelling in IPF: The Challenges, Opportunities & Next Steps**

As we seek to refine our understanding of IPF pathogenesis and therapeutic response, advanced disease modelling remains a critical challenge. This interactive roundtable discussion allows you to share your thoughts on the current limitations in modelling approaches, strategies for improvement, and the feasibility of global initiatives to enhance research resources.

- **Beyond the Bleomycin Model:** Discussing alternative models such as patient-derived organoids, AI-driven models, and humanized systems to improve disease predictability
- **Tissue Scarcity:** Exploring the feasibility of a coordinated effort to collect biopsy samples globally for research, addressing logistical and ethical concerns
- **Explanted Lungs in Research:** Evaluating the role of lungs from transplant recipients in studying disease progression, and their relevance to early-stage IPF
- **Building Predictive Models:** Identifying criteria for next-gen models that integrate multi-omics and patient samples to enhance translational relevance

**12:00 Roundtable Discussion: Designing for Impact: Ensuring New IPF Therapies Stand Out in an Evolving Treatment Landscape**

As the IPF treatment landscape evolves, developers must consider how to design therapies that stand out not only scientifically but also clinically and commercially. This interactive discussion will explore how to ensure new treatments demonstrate enough value for clinical adoption, regulatory approval, and long-term reimbursement success.

- **Setting a Higher Bar for Efficacy:** Assessing whether small reductions in lung function decline are enough, or if novel therapies need to show broader benefits in patient well-being and disease modification
- **Trial Design for Differentiation:** Exploring how study endpoints, patient selection, and biomarker strategies can help new therapies stand out in a space where standard-of-care options are expanding
- **The Reality of Combination Therapy:** Discussing how to evaluate the standalone and additive effects of therapies that will likely be used in combination rather than as monotherapies
- **Future Considerations for Reimbursement:** Examining how payers might assess value when multiple treatment options exist, and whether cost-effectiveness modeling should be incorporated into early development strategies

**12:30 Lunch Break**

## Track 1: Emerging Biology & Early Translational

### Mapping the Next Frontier in IPF Drug Development with Novel Therapeutic Approaches

**1:30 Panel Discussion: Rethinking IPF Drug Development: Learning from the Past & Defining the Future of Target Discovery**

- Assessing past and present targets, what has the field learned from antifibrotic failures, and is there still potential in pathways like TGF-β?
- Exploring emerging therapeutic strategies from repair and regeneration to RNA-based therapies, cell and gene therapy, and immunomodulation
- Identifying unmet opportunities by exploring what mechanisms remain underexplored, where should research efforts be focused next to drive meaningful progress?

**Cara Williams,** Vice President, Head of Preclinical Biology: Inflammation & Immunology, **Pfizer**

**Dori Thomas-Karyat**, Founder & Chief Executive Officer, **Synthis Therapeutics**

**Min Lu**, Executive Director, Biology, **Eli Lilly and Company**

## Track 2: Late Translational & Clinical

### Innovations in Clinical Development & Clinical Trial Enrichment for Improved Probability of Therapeutic Outcome

**1:30 Stratifying Patients for Improved Trial Outcomes – High-Risk vs Low-Risk in the Maverick IPF Survival Trial**

- Exploring the premise of stratifying patients by risk level (high vs low)
- Shifting focus from FVC decline to survival as a primary endpoint in clinical trials, and how this could offer more meaningful insights into treatment efficacy for IPF
- Discussing the role of proteomics and biomarkers in identifying high-risk patients and optimizing trial design to better reflect patient populations likely to benefit from treatment

**Fernando Martinez**, Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine, **University of Massachusetts Medical School**

**2.00 Examining Cell Therapy in IPF: Harnessing ADCs & Leveraging Non-Cytotoxic TGF-β Payload to Selectively Target IPF & Reduce Toxicity**

- Exploring the potential of ADCs to selectively deliver therapeutics while minimizing systemic toxicity
- Revaluating specific targeting of TGF-β in fibrosis by leveraging non-cytotoxic payloads to modulate TGF-β signaling without adverse effects
- Integrating ADCs with emerging approaches to enhance efficacy and safety in IPF treatment

**Dori Thomas-Karyat**, Founder & Chief Executive Officer, **Synthis Therapeutics**

**2.00 Panel Discussion: Practical Considerations for Optimizing Spirometry & Other Endpoints in Pulmonary Fibrosis Clinical Trials**

- A moderated discussion between PureTech and Vitalograph about the common challenges that clinical trials face and practical strategies to overcome them
- Puretech review how they designed and conducted their Phase 2b IPF study to maximise data quality
- Key learnings PureTech are taking into their Phase 3 preparations
- A study coordinator's perspective on how sponsors can further support teams at sites to improve patient experiences and ease of trial conduct is shared.

**Claire Cherry**, Scientific Affairs Director, **Vitalograph**

**Camilla Graham**, Senior Vice President, Medical Affairs, **PureTech Health**

**Catherine Elliot**, Clinical Trials Project Director, **Vitalograph**

**2:30 IPF Treatment: Exploring Novel Approaches for Disease Modification**

- Inhaled antisense as a novel paradigm for lung therapeutics
- Advancing innovative technology enables the targeting, interrogation, and validation of genes associated with IPF that may be difficult to reach with other approaches
- Exploring MUC5B as a Novel IPF Target: Pros, Cons, and Proof-of-Concept Data

**Raghu Kumar**, Senior Scientist, Drug Discovery, **Ionis Pharmaceuticals**

**2:30 Integrating Patient Perspectives Into Clinical Trial Design: Lessons from Recruitment & Outcome Selection**

- Selecting outcomes that reflect real patient priorities, from symptom relief to quality of life to align trials with patient needs
- Exploring strategies that have succeeded (and failed) in engaging and keeping patients in trials to enhance recruitment and retention
- Ensuring protocols are patient-friendly while maintaining scientific and regulatory rigor to optimize clinical trial design

**Emilie Millaire**, Pulmonologist, CIC Canada, Laval University, **and University of Montreal**

**3.00 Afternoon Break & Poster Session**

## Exploring the Latest Clinical Progress in the Pulmonary Fibrosis Landscape

**3.30 Panel Discussion: Hear from the Clinicians – What Will Constitute First-Line Therapy for IPF in an Evolving Landscape?**

- With new therapies on the horizon, the IPF treatment landscape is evolving. This panel brings together leading clinicians and academics to explore how emerging drugs will fit into current treatment paradigms. Experts will discuss the clinical decision-making process for first-line therapy, balancing efficacy, safety, and patient-specific factors.

**Toby Maher**
Professor of Clinical Medicine
**University of Southern California**

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**Justin Oldham**
Associate Professor
**University of Michigan**

**Mary Strek**
Professor of Medicine, Director, Interstitial Lung Disease Program
**University of Chicago**

**Joyce Lee**
Professor, Medicine-Pulmonary Sciences & Critical Care
**University of Colorado Denver**

**4:15 Advancing Rentosertib: An AI-Discovered TNIK Inhibitor Targeting IPF in Global Phase 2 & 3 Trials**

**Carol Ann Satler**
Senior Vice President, Clinical Development
**Insilico Medicine**

- Detailing the discovery and development of Rentosertib (INS018_055), a first-in-class small molecule TNIK inhibitor identified through end-to-end generative AI
- Overview of clinical progression: positive safety and efficacy signals from a completed Phase 2a trial, with Phase 2b in the US and a Phase 3 trial underway in China
- Reflections on the integration of AI in early discovery and translational development, and navigating multinational clinical trial strategies for IPF

# Conference Day One
## Wednesday, August 20





**Camilla Graham**
Senior Vice President, Medical Affairs
**PureTech Health**

**4.45** **Advancing Anti-Fibrotic Innovation: A Clinical Update on Deupirfenidone & Considerations for Real-World Access**

- Overview of the clinical development journey of deupirfenidone, including key learnings from the Phase 2b study and plans for advancing to Phase 3
- Discussion of trial design rationale, patient population, endpoints, and positioning within the current IPF treatment landscape

**Aditya Patel**
Executive Director, Pulmonary Clinical Development
**Bristol Myers Squibb**

**5.15** **Progressing Admilparant, an LPA1 Antagonist, Through Phase 3 for IPF & PPF: An Update on Progress, Perspectives & Positioning**

- Explore the latest developments in the Phase 3 program, including trial design evolution, enrollment strategy, and global rollout progress
- Reflect on key learnings from the Phase 2 study and how they informed the transition to late-stage development
- Discuss how LPA1 antagonism may fit into an increasingly crowded and combination-driven pulmonary fibrosis treatment landscape

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**5.45** **Chairs Closing Remarks**

**5:50** **Poster Session & Networking Drinks Reception**
Unwind and connect with fellow attendees over drinks while exploring cutting-edge poster presentations in the pulmonary fibrosis space. This informal session offers the perfect opportunity to spark meaningful conversations, share your latest developments, and gain fresh insights from peers across the field. Whether you're presenting or just browsing, this is a session that cannot be missed!

**End of Day One**

> "I really enjoyed the speed networking hour. The structured interaction environments are really helpful to meet lots of different people!"
>
> **Sonata Therapeutics**

> "Opportunity to meet stakeholders of different backgrounds and areas to form a new ideas and thoughts"
>
> **Accendatech**

# Conference Day Two
## Thursday, August 21





**8:30** **Light Breakfast**

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**8:55** **Chairs Opening Remarks**

**9:00** **AI Showcase for Drug Development & Advances in Fibrosing Lung Disease**

**Elizabeth Estes**
Executive Director
**OSIC ILD**

- Learn about the robust clinical data curation, global normalization and advanced data power to drive radical progress in drug development for fibrosing lung diseases
- See quantifiable Artificial Intelligence (AI) advances that this data has already powered, including various disease quantification tools and emerging innovations
- Discuss the long-term vision of imaging in fibrosing lung diseases, including the potential inclusion of lung cancer screening for risk scoring of ILA's
- Learn about Project Opus, a new, real-time observational study that applies AI and machine learning technology to the spirometry, environmental, and imaging data

**9:30** **Panel Discussion: Rethinking Endpoint Selection to Accelerate Innovation in Pulmonary Fibrosis Drug Development**

Imaging offers a direct window into disease progression, but its role in predicting treatment response and improving trial design remains uncertain. While AI-driven imaging shows promise, regulatory acceptance and standardization are key challenges. This panel will explore how imaging can enhance clinical trials and accelerate drug development.
Key Discussion Points:

- What role can imaging play as a surrogate or co-primary endpoint? How close are we to standardized, validated imaging biomarkers, and what can be learned from oncology or neurology?
- How should the field approach integration of patient-reported outcomes and real-world evidence to reflect lived patient experience?
- What are the key regulatory considerations in validating novel endpoints, whether AI-derived, biomarker-based, or functional? How can stakeholders proactively align on evidentiary standards?
- How can trial sponsors, academic experts, and regulators collaborate to build a more flexible, data-driven framework for endpoint selection in future studies?

**Toby Maher**
Professor of Clinical Medicine
**University of Southern California**

**Bertil Lindmark**
Chief Medical Officer
**Vicore Pharma**

**Paul Ford**
**Independent Consultant**
Former Chief Medical Officer
**Galecto**

**10:00** **Morning Break**

## Track 1: Emerging Biology & Early Translational

### Assessing Repair & Regeneration: A New Era or the Next Clinical Trap?

**11:00 Deep Diving into the Biology of Pulmonary Fibrosis: Where Does Repair, Regeneration & Remodeling Play a Role?**

- Examining key cell types involved in fibrosis progression and their role in repair and regeneration
- Identifying where in the disease process intervention could drive meaningful tissue repair and prevent irreversible damage
- Exploring emerging strategies in cell therapy, regenerative medicine, and molecular targets to restore lung function

**Darrell Kotton**, Professor of Medicine & Director of the Center for Regenerative Medicine (CReM), **Boston University and Boston Medical Center**

## Track 2: Late Translational & Clinical

### Innovations in Clinical Development

**11:00 Redefining Cough in IPF: Central Mechanisms, Patient Impact & Therapeutic Opportunity**

- Exploring refractory chronic cough as a distinct clinical burden in IPF and ILDs: what are we missing in current trial designs?
- Is cough the "itch of the lung"? Drawing translational parallels between chronic cough and other hypersensitization syndromes like atopic dermatitis
- Mechanistic insights: The role of centrally acting, unscheduled opioid receptor modulators in treating IPF-related cough versus peripherally targeted approaches
- Clinical considerations in trial design, endpoint selection, and measuring meaningful improvement for patients living with IPF-related chronic cough

**James Casella**, Chief Development Officer, **Trevi Therapeutics**

# Conference Day Two
## Thursday, August 21



**11:30 Promoting Tissue Regeneration Through Modulation of AT2 Receptor Pathway**

- Harnessing the AT2 receptor pathway to drive lung tissue repair and counteract fibrotic remodeling in pulmonary diseases, a distinct mechanism from conventional antifibrotics
- Exploring the regenerative potential of C21, an AT2R agonist, to restore alveolar epithelial function and promote vascular integrity
- Advancing a new class of regenerative therapies by targeting endogenous repair pathways, with a focus on improving clinical outcomes through enhanced lung function, symptom relief, and disease modification.

**Ahmed Mousa**, Chief Executive Officer, **Vicore Pharma**

**11:30 Designing Clinical Trials with Patients in Mind to Align Scientific Goals with Real-World Needs**

- Integrating fatigue, cough, and other patient-centered outcomes into clinical trial design – How can we better capture the true impact of therapies on quality of life?
- Developing endpoints that go beyond regulatory approval to deliver meaningful data for patients and clinicians
- Leveraging Insight from Patient Organizations to improve recruitment, retention and relevance

**Jalpa Patel**, Scientific Director, Specialty Pipeline, Global Medical Affairs, **AbbVie**

**12:00 Exploring Elimination of Senescent Cells Through Activation of Endogenous Immune Surveillance Mechanism**

- Investigating the role of tissue-resident immune cells in identifying and clearing senescent cells implicated in pulmonary fibrosis progression
- Evaluating Deciduous Therapeutics' novel strategy to restore immune surveillance as a therapeutic approach to halt or reverse fibrotic remodeling
- -Highlighting preclinical data supporting immune modulation over direct senolytic strategies to improve safety, selectivity, and long-term efficacy in IPF

**Robin Mansukhani**, Chief Executive Officer, **Deciduous Therapeutics**

**12:00 How Can the Evolution of Trials & Guidelines in Pulmonary Hypertension Inform Future Efforts in IPF/ILD?**

- Lessons from the evolution of endpoints in PH trials: from 6-minute walk test to composite and patient-centric outcomes
- Applicability of combination and sequential therapy strategies in IPF/ILD clinical development
- How changes in PH guidelines have influenced trial design—and what that could mean for future IPF/ILD guidance

**Franck Rahaghi**, Executive Director of Cardiopulmonary, Global Medical Affairs, **United Therapeutics Corp**

**12:30 Lunch Break**

**1:30 Exploring Elimination of Senescent Cells Through Harnessing RNA Based Biology**

- SENISCA have discovered a new and druggable cause of cellular ageing, dysregulated mRNA processing
- We have designed an RNA therapeutic with a unique MoA capable of restoring levels of splicing regulators back within their homeostatic limits for selective reprogramming of senescent cells
- We have demonstrated efficacy for our new approach in primary human IPF patient cells and in precision cut lung slices from patients with IPF and other interstitial fibrosis disorders

**Lorna Harries**, Chief Scientific Officer & Co-founder, **SENISCA** and Professor of **Molecular Genetics, University of Exeter**

**1:30 Redefining the Diagnostic Landscape: Early Detection of ILD & the Clinical Relevance of ILA**

- Clarifying the distinction between ILA and early-stage ILD to inform diagnosis and management
- Predicting progression to ILD using imaging, exposure history, and autoimmune features
- Establishing early detection infrastructure through dedicated ILA clinics and surveillance strategies

**Mary Strek**, Professor of Medicine

Director, Interstitial Lung Disease Program, **University of Chicago**

**2:00 Panel Discussion: Exploring the Feasibility and Future of Lung Regeneration in IPF: Challenges, Opportunities, and Emerging Therapies**

Panel Discussion Points:

- Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
- What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
- Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
- How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
- Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?

**Matthew Thomas**, Department Head, Immunology & Respiratory, **Boehringer Ingelheim**

**Lorna Harries**, Chief Scientific Officer & Co-founder, SENISCA and Professor of Molecular Genetics, **University of Exeter**

**Ahmed Mousa**, Chief Executive Officer, **Vicore Pharma**

**Marco Quarta**, Co-Founder and Chief Scientific Officer, **Rubedo Life Sciences**

**2:00 Collaborative Acceleration: PROLIFIC Consortium Update on Advancing PF Research Through Real-World Data & Biomarker Integration**

- Explore how the PROLIFIC Consortium is leveraging longitudinal clinical data and biosamples across diverse care settings to refine our understanding of pulmonary fibrosis progression and treatment outcomes
- Get the latest updates on multi-center efforts to identify, validate, and implement biomarkers that can predict progression, inform trial design, and personalize care
- Understand how this industry-funded initiative is creating a robust framework to support open science, harmonized data collection, and future clinical trials by bringing together academic centers, biobanks, and industry partners

**Peter Schafer**, Chair, Prognostic Lung Fibrosis Consortium (PROLIFIC), **Pulmonary Fibrosis Foundation**

# Conference Day Two
## Thursday, August 21





**2:30** **Afternoon Break**

### What's Next: Explore Emerging Therapeutics with the Potential to Revolutionize the Landscape

**Iris Alroy**
Co-Founder & Scientific Chief & Officer
**Anima Biotech**

**3:30** **Unlocking mRNA Biology for IPF: Advancing Small Molecule Approaches to Modulate Protein Translation**

- Session Reserved for Anima Biotech

**Ole Joergen Kaasboell**
Chief Scientific Officer & Co-founder
**Tribune Therapeutics**

**3:50** **Targeting Pro-Fibrotic Macrophage Signatures & CCN Biology: Translating Preclinical Insights into a Next-Gen IPF Therapeutic**

- Highlighting precision-cut lung slices and airway basal cell bronchosphere assays as predictive tools for translational validation
- Demonstrating modulation of pro-fibrotic macrophage markers in human-derived systems in collaboration with FibroFind and Antiverse
- Exploring the therapeutic rationale behind targeting CCN signaling pathways in the context of previous setbacks and renewed opportunities in IPF

**Jonas Hallén**
Chief Medical Officer & Co-Founder
**Calluna Pharma**

**4:10** **Targeting the Upstream Pro-Fibrotic Amplifier S100A4: A Differentiated Approach to Treating IPF**

- Addressing the complexity of IPF pathogenesis: Mechanistic rationale for targeting S100A4 in fibrosis - an evolutionary conserved amplifier of inflammation and persistent fibrogenesis
- Impact of S100A4 suppression across preclinical and translational assays of fibrosis and inflammation
- Introducing CAL101: A first-in-class anti-S100A4 mAb being evaluated in IPF patients in the phase 2 AURORA study

**Eugènia Ruiz Cánovas**
Chief Scientific Officer
**GAT Therapeutics**

**4:30** **Exploring a Novel TGF-β Pathway Modulator**

- GTX-11, an orally available TGF-β pathway modulator, has shown potent anti-fibrotic, anti-inflammatory, and vascular-protective effects across multiple preclinical models, including bleomycin-induced lung fibrosis, patient-derived fibroblasts, and precision-cut lung slices (PCLS)
- With an excellent preclinical safety and toxicology profile, GTX-11 effectively reduces SMAD2/3 activation, fibroblast-to-myofibroblast transition, and vascular dysfunction, positioning it as a promising therapeutic candidate
- Now in Phase I clinical trials, GTX-11 represents a promising new approach for treating fibrotic interstitial lung diseases (ILDs), offering potential advantages over existing therapies

**Fernando Martinez**
Joseph D. Early Chair in Biomedical Research, Pulmonary Medicine
**University of Massachusetts Medical School**

**4:50** **Chair's Closing Remarks**

**5:00** **End of Day Two - Goodbye's & 'Until Next Year's'**

# Partner with the 9th IPF Summit

9th Annual IPFSummit
August 19-21, 2025 | Boston, MA

## Capitalize on the Industry's Momentum & Solidify Your Role in Advancing Pulmonary Fibrosis Therapeutics to Patients

**With Boehringer's Phase III success for nerandomilast, we are entering a new era for IPF drug development**. After years of frustration and failed trials, this long-awaited momentum is reigniting hope and bringing a long-overdue vote of confidence to the field. It's a pivotal moment, one that is energizing the global community and accelerating investment across discovery, translational, and clinical programs.

**The appetite for innovation in progressive pulmonary fibrosis has never been greater**. Drug developers worldwide are doubling down on fibrosis pipelines, and the demand for strategic, science-driven partnerships is rapidly rising. The **9th IPF Summit** convenes a uniquely focused audience of R&D leaders and decision-makers actively seeking solutions to their most pressing challenges.

**For almost a decade, the IPF Summit has been the trusted partner platform** for service providers to elevate their brand, showcase technical expertise, and forge lasting relationships with the industry's key players.

If you're looking to capitalize on this infectious industry energy, **join us to position your company at the forefront of this space**, we will work with you to craft a bespoke package that aligns your brand with the opportunity in pulmonary fibrosis.

**Get in touch to explore how we can spotlight your solutions.**

**Molly Biggin**
Business Development Manager
**9th IPF Summit**

## Drug Developers are Actively Seeking:

### Preclinical Model Developers with Expertise in Mimicking Lung Pathophysiology & Microenvironment

Vendors offering innovative in vivo and ex vivo systems that accurately replicate the dynamic progression of pulmonary fibrosis for better translational predictability

### Imaging & Diagnostic Technology Providers Enabling Real-Time Disease Tracking & Early Intervention

Solutions spanning advanced imaging modalities, screening platforms, and digital tools to enhance early detection, monitor therapeutic efficacy, and inform treatment strategies

### Biomarker Solution Providers Delivering End-to-End Platforms from Discovery to Clinical Application

Partners offering robust biomarker development, including minimally invasive and emerging biomarkers, to support patient stratification, disease monitoring, and therapeutic response

### Preclinical CROs with Specialized Expertise in Fibrosis Biology & Target Validation

Organizations equipped with deep biological insight and technical capabilities to accelerate target discovery, mechanism elucidation, and early-stage drug design

### Clinical CROs Experienced in IPF & ILD Trial Design & Execution

CRO partners with proven track records in managing the complexities of rare respiratory trials, including protocol development, site selection, patient recruitment, and regulatory alignment

## How You Can Get Involved

- Exhibition Booth to Raise Awareness and Provide Hands-On Demonstrations
- Data Driven or Case-Study Led Presentations to Position Yourself as a Thought Leader
- Exclusive Access to the Delegate List to Plan your 1-2-1 Conversations in Advance
- Hosted Drinks Reception or Private Lunch for Exclusive Time with Your Target Audience
- Expert Panel Discussion Inclusion to Shape Forward Thinking
- On-Site & Web Branding to Highlight Your Company at the Forefront of this Space

# 2025 Partners

## OSIC ILD – Expertise Partner

Open Source Imaging Consortium (OSIC) – a global 501(c)(3), not-for-profit cooperative effort between academia, industry and patient advocacy groups – was created to look at lung diseases differently, and to drive collaboration between unlikely partners. Our goal is to make rapid, open source advances in the detection and diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) for the countless patients and their caregivers living with these diseases. OSIC is a global effort using real-world curated data machine learning and collaboration to fight ILDs.

**www.osicild.org**

## Qureight – Expertise Partner

Qureight is techbio company based in Cambridge UK. Founded by doctors and scientists it aims to be THE data platform for lung and heart disease. It structures data from health care and biopharma partners to find new endpoints, speed up clinical trials and help bring drugs to the market. By analysing data on it's cloud based platform, Qureight allows collaborators

to build machine learning models to better understand diseases. It has a current focus in IPF, ILD, Pulmonary Hypertension and Lung Cancer. It recently published a landmark paper in AJRCCM detailing 4 deep learning imaging models in IPF.

**www.qureight.com**

## FibroFind - Expertise Partner

FibroFind specialises in the application of advanced technologies for interrogating fibrosis biology. Leveraging our expertise, we have developed proprietary bioreactor-cultured precision-cut tissue slices (PCTS) that demonstrate exceptional performance in biomarker identification, toxicology, target discovery and drug efficacy evaluation. By harnessing robotics, AI-guided data analysis and a highly skilled team, FibroFind ensures unparalleled quality in all studies. Our portfolio includes PCTS from healthy and diseased (IPF, ILD, COPD) lungs, in 24 and 96 well formats, allowing us to customise studies to meet your specific needs and deliver results that drive your research forward

**www.fibrofind.com**

## THORASYS - Program Partner

THORASYS is a global med-tech company that develops, manufactures, and markets airwave oscillometry (AOS) technologies to support early detection and continued monitoring of chronic respiratory diseases such as asthma and COPD. Our tremoFlo® Airwave Oscillometry System (AOS®) is a compact and portable device that provides an effortless assessment of lung function providing insights on airway mechanics and air ventilation status in the lung that lead to output changes such as FVC. The quantitative measures are highly correlated to imaging assessments, especially in diseases such as IPF.

**www.thorasys.com**

# 2025 Event Partners

## HEC Pharma - Innovation Partner

HEC Pharm, listed on the Hong Kong Stock Exchange, is a fully integrated pharmaceutical company with a strong focus on infectious diseases, oncology, metabolic disorders, and other chronic conditions. The company has three innovative drugs approved and a robust pipeline of over 40 candidates in various stages of development. Established in 2005, HEC's R&D center in Guangdong, China, employs more than 1,000 scientists and provides end-to-end drug discovery and development capabilities. Its technology platforms span all major drug modalities, including small molecules, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell therapies.

**www.hec-research.com**

## Vitalograph Inc – Hosting Partner

Vitalograph provides sponsors with everything needed to collect, QC, and report on Respiratory endpoint data for the following assessments: FEV1, FVC, SVC, PEF, ECG, ePRO/ eCOA, FeNO, DLCO, 6MWT, and objective cough counting. Our knowledgeable and responsive teams of dedicated project and data managers, clinical respiratory physiologists, cough analysts, software development engineers, in-house QA and logistic specialists, plus highly-experienced site support staff, are what make our innovative and personalized solutions possible.

**www.vitalograph.com**

## Nordic Bioscience - Exhibition Partner

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at

**www.nordicbioscience.com**

## Worldwide Clinical Trials – Exhibition Partner

**www.worldwide.com**

## Strados Labs – Exhibition Partner

Strados Labs partners with IPF drug developers to collect real-world, objective measures of subjects' cough and lung health to complement subjective patient self-reporting. Using a combination of audio and motion data, the RESP® Biosensor remotely and continuously captures coughing and lung sounds including crackles as well as respiratory rate, activity levels, and sleep/wake to offer stronger insight into treatment response. Designed for daily life, the RESP Biosensor is wireless, discreet and doesn't interfere with daily routines. The biosensor has 2 FDA 510(k) clearances, a CE mark and is used in clinical trials across 4 continents.

**www.stradoslabs.com**

# 2025 Event Partners

## Q2 Solutions – Exhibition Partner

Rules-Based Medicine (RBM), a Q2 Solutions company, provides specialty immunoassay testing that solves complex drug development challenges. RBM offers one of the most comprehensive menus of quantitative protein biomarkers, including multiplexed immunoassays (Luminex®) and ultrasensitive immunoassays. RBM offers a suite of internally developed and validated biomarkers to support new therapies for idiopathic pulmonary fibrosis (IPF). Chosen in collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC), these markers have utility in characterizing epithelial damage, fibrosis, inflammation and thrombosis.

**www.rbm.iqvia.com**

## MannKind Corporation – Industry Partner

MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, IPF, PAH and NTM lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

**www.mannkindcorp.com**

# REGISTRATION INFORMATION

## TOP 3 REASONS TO ATTEND

**1** **Follow the Full Journey from Bench to Bedside**

Gain unparalleled insight into the translational path of Boehringer Ingelheim's clinical candidate, as experts share lessons learned from early discovery through to Phase 3, illuminating what it takes to advance a successful IPF program.

**2** **Broaden Your Network Across a Thriving & Evolving IPF Community**

Connect with an expanded mix of established players and fresh innovators entering the IPF space, offering an exceptional chance to diversify your collaborations and uncover novel scientific and strategic synergies.

**3** **Stay Ahead in an Era of Rapid Scientific & Clinical Evolution**

Navigate the changing IPF landscape with the latest updates on targets, mechanisms, patient stratification, and endpoints to future-proof your therapeutic strategies and stay competitive in a dynamic field.

## 3 EASY WAYS TO BOOK

www.ipf-summit.com/take-part/register/.com

+1 617 455 4188

Email: info@hansonwade.com

| Drug Developer Pricing | Register & Pay by Friday, July 18 & Save up to $500! | On the Door Price |
|---|---|---|
| Conference + Pre-Conference Workshop Day | $3,697 | $4,197 |
| Conference Only | $2,699 | $2,999 |
| **Academic & Not-for-Profit** | Register & Pay by Friday, July 18 & Save up to $500! | On the Door Price |
| Conference + Pre-Conference Workshop Day | $3,097 | $3,597 |
| Conference Only | $2,299 | $2,599 |
| **Solution Provider Pricing** | Register & Pay by Friday, July 18 & Save up to $500! | On the Door Price |
| Conference + Pre-Conference Workshop Day | $4,597 | $5,097 |
| Conference Only | $3,399 | $3,699 |

## Team Discounts

**10% discount – 2 delegates**

**15% discount – 3 delegates**

**20% discount – 4+ delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates. For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com


## Venue

**Hilton Boston Park Plaza**

50 Park Plaza, Boston, MA 02116, United States

**www.hilton.com/en/hotels/bossrhh-hilton-boston-park-plaza/**

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom